Literature DB >> 16706846

Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons.

Anna Lisa Muntoni1, Giuliano Pillolla, Miriam Melis, Simona Perra, Gian Luigi Gessa, Marco Pistis.   

Abstract

The noradrenergic pathway arising from the locus coeruleus (LC) is involved in the regulation of attention, arousal, cognitive processes and sleep. These physiological activities are affected by Cannabis exposure - both in humans and laboratory animals. In addition, exogenous cannabinoids, as well as pharmacological and genetic manipulation of the endocannabinoid system, are known to influence emotional states (e.g. anxiety) for which a contributory role of the LC-noradrenergic system has long been postulated. However, whether cannabinoid administration would affect the LC neuronal activity in vivo is still unknown. To this end, single-unit extracellular recordings were performed from LC noradrenergic cells in anaesthetized rats. Intravenous injection of both the synthetic cannabinoid agonist, WIN55212-2, and the main psychoactive principle of Cannabis, Delta9-tetrahydrocannabinol, dose-dependently increased the firing rate of LC noradrenergic neurons, with WIN55212-2 being the most efficacious. Similar results were obtained by the administration of these drugs into a lateral ventricle. Cannabinoid-induced stimulation of LC noradrenergic neuronal activity was counteracted by SR141716A, a cannabinoid receptor antagonist/reverse agonist, which by itself slightly reduced LC discharge rate. Moreover, WIN55212-2 suppressed the inhibition of noradrenergic cells produced by stimulation of the major gamma-aminobutyric acid (GABA)ergic afferent to the LC, the nucleus prepositus hypoglossi. Altogether, these findings suggest the involvement of noradrenergic pathways in some consequences of Cannabis intake (e.g. cognitive and attention deficits, anxiety reactions), as well as a role for cannabinoid receptors in basic brain activities sustaining arousal and emotional states.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706846     DOI: 10.1111/j.1460-9568.2006.04759.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  46 in total

Review 1.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 3.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

4.  Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex.

Authors:  Veronica C Oropeza; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

5.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 6.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

7.  Cannabinoids and novelty investigation: influence of age and duration of exposure.

Authors:  Krysta M Fox; Robert C Sterling; Elisabeth J Van Bockstaele
Journal:  Behav Brain Res       Date:  2008-10-05       Impact factor: 3.332

8.  Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.

Authors:  Alex Villanueva; Sertac M Yilmaz; William R Millington; Rodolfo A Cutrera; David G Stouffer; Loren H Parsons; Joseph F Cheer; Carlos Feleder
Journal:  Shock       Date:  2009-12       Impact factor: 3.454

Review 9.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.